The stock has a 36-month beta value of 0.75. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NBY is 4.89M, and at present, short sellers hold a 0.37% of that float. On October 29, 2024, the average trading volume of NBY was 2.55M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NBY) stock’s latest price update
Novabay Pharmaceuticals Inc (AMEX: NBY)’s stock price has plunge by 12.65relation to previous closing price of 0.55. Nevertheless, the company has seen a 4.91% surge in its stock price over the last five trading sessions. businesswire.com reported 2024-09-20 that NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NovaBay Pharmaceuticals, Inc.’s (NYSE American: NBY) Avenova brand and business to Physician Recommended Nutriceuticals, LLC for $9.5 million in cash is fair to NovaBay shareholders. Halper Sadeh encourages NovaBay shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper.
NBY’s Market Performance
Novabay Pharmaceuticals Inc (NBY) has seen a 4.91% rise in stock performance for the week, with a -10.03% decline in the past month and a 3.04% surge in the past quarter. The volatility ratio for the week is 8.71%, and the volatility levels for the past 30 days are at 7.52% for NBY. The simple moving average for the past 20 days is -1.18% for NBY’s stock, with a -77.31% simple moving average for the past 200 days.
Analysts’ Opinion of NBY
Many brokerage firms have already submitted their reports for NBY stocks, with Ladenburg Thalmann repeating the rating for NBY by listing it as a “Buy.” The predicted price for NBY in the upcoming period, according to Ladenburg Thalmann is $1.10 based on the research report published on September 18, 2019 of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NBY reach a price target of $4. The rating they have provided for NBY stocks is “Buy” according to the report published on July 06th, 2018.
Laidlaw gave a rating of “Buy” to NBY, setting the target price at $8 in the report published on November 15th of the previous year.
NBY Trading at 6.46% from the 50-Day Moving Average
After a stumble in the market that brought NBY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.17% of loss for the given period.
Volatility was left at 7.52%, however, over the last 30 days, the volatility rate increased by 8.71%, as shares sank -8.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.10% upper at present.
During the last 5 trading sessions, NBY rose by +4.91%, which changed the moving average for the period of 200-days by -89.85% in comparison to the 20-day moving average, which settled at $0.6274. In addition, Novabay Pharmaceuticals Inc saw -91.32% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NBY
Current profitability levels for the company are sitting at:
- -0.38 for the present operating margin
- 0.59 for the gross margin
The net margin for Novabay Pharmaceuticals Inc stands at -0.89. The total capital return value is set at -14.41. Equity return is now at value -265.29, with -105.75 for asset returns.
Based on Novabay Pharmaceuticals Inc (NBY), the company’s capital structure generated 1.44 points at debt to capital in total, while cash flow to debt ratio is standing at -1.41. The debt to equity ratio resting at -3.26. The interest coverage ratio of the stock is -6.23.
Currently, EBITDA for the company is -4.8 million with net debt to EBITDA at -0.28. When we switch over and look at the enterprise to sales, we see a ratio of 0.35. The receivables turnover for the company is 21.96for trailing twelve months and the total asset turnover is 3.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.62.
Conclusion
To sum up, Novabay Pharmaceuticals Inc (NBY) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
